These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16142565)

  • 1. Increase in serum magnesium level in haemodialysis patients receiving sevelamer hydrochloride.
    Mitsopoulos E; Griveas I; Zanos S; Anagnostopoulos K; Giannakou A; Pavlitou A; Sakellariou G
    Int Urol Nephrol; 2005; 37(2):321-8. PubMed ID: 16142565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA; Burke SK; Dillon MA
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
    Wilkes BM; Reiner D; Kern M; Burke S
    Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
    Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
    Gallieni M; Cozzolino M; Carpani P; Zoni U; Brancaccio D
    J Nephrol; 2001; 14(3):176-83. PubMed ID: 11439741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
    Liu YL; Lin HH; Yu CC; Kuo HL; Yang YF; Chou CY; Lin PW; Liu JH; Liao PY; Huang CC
    Ren Fail; 2006; 28(8):701-7. PubMed ID: 17162430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.
    Goldberg DI; Dillon MA; Slatopolsky EA; Garrett B; Gray JR; Marbury T; Weinberg M; Wombolt D; Burke SK
    Nephrol Dial Transplant; 1998 Sep; 13(9):2303-10. PubMed ID: 9761513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
    Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
    Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
    Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
    Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
    Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
    Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
    Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
    Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
    Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability.
    de Francisco AL; Leidig M; Covic AC; Ketteler M; Benedyk-Lorens E; Mircescu GM; Scholz C; Ponce P; Passlick-Deetjen J
    Nephrol Dial Transplant; 2010 Nov; 25(11):3707-17. PubMed ID: 20530499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children.
    Mahdavi H; Kuizon BD; Gales B; Wang HJ; Elashoff RM; Salusky IB
    Pediatr Nephrol; 2003 Dec; 18(12):1260-4. PubMed ID: 14586677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
    Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
    Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders.
    Galassi A; Spiegel DM; Bellasi A; Block GA; Raggi P
    Nephrol Dial Transplant; 2006 Nov; 21(11):3215-22. PubMed ID: 16877490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New strategy to attenuate pulse wave velocity in haemodialysis patients.
    Takenaka T; Suzuki H
    Nephrol Dial Transplant; 2005 Apr; 20(4):811-6. PubMed ID: 15772266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients.
    Lin HH; Liou HH; Wu MS; Lin CY; Huang CC
    Nephrology (Carlton); 2014 Nov; 19(11):672-8. PubMed ID: 25113414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.